Result Update:SBI Life Insuran
Axis Direct
We maintain our BUY recommendation on the stock
Broker Research reports: latest Upgrades
for all stocks
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
Load latest
Google or static link led you to an intermediate page.
- All Recent
- Upside
- Buy
- Sell
- Recent Upgrades
- Recent Downgrades
- IPO
- Sector Updates
- Most Recent
- Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 Apr 2025 | SBI Life Insurance |
Axis Direct
|
1763.90 | 1900.00 | 1695.10 (4.06%) | 7.72 |
Buy
|
||||
| 25 Apr 2025 | ACC |
Axis Direct
|
1941.40 | 2420.00 | 1938.00 (0.18%) | 24.65 |
Buy
|
||||
| 25 Apr 2025 | Dalmia Bharat |
Axis Direct
|
2089.30 | 2260.00 | 1965.90 (6.28%) | 8.17 |
Buy
|
||||
| 25 Apr 2025 | Nestle |
Axis Direct
|
2392.60 | 2675.00 | 2413.50 (-0.87%) | 11.80 |
Buy
|
||||
| 25 Apr 2025 | Laurus Labs |
BOB Capital Markets Ltd.
|
597.05 | 641.00 | 625.65 (-4.57%) | Target met |
Hold
|
||||
| 25 Apr 2025 | SBI Life Insurance |
BOB Capital Markets Ltd.
|
1763.90 | 2008.00 | 1695.10 (4.06%) | 13.84 |
Buy
|
||||
| 25 Apr 2025 | Axis Bank |
BOB Capital Markets Ltd.
|
1197.80 | 1354.00 | 1166.30 (2.70%) | 13.04 |
Hold
|
||||
| 24 Apr 2025 | Axis Bank |
Sharekhan
|
1197.80 | 1400.00 | 1207.10 (-0.77%) | 16.88 |
Buy
|
Mixed bag Q4, eyeing better FY26
Sharekhan
Q4FY25 earnings were a mixed bag. Net interest income (NII), at Rs. 13,811 crore (in line), grew by ~6% y-o-y/2%q-o-q. NIMs marginally improved by 4 bps q-o-q to 3.97% led by better asset quality and income tax refund.
|
|||
| 24 Apr 2025 | LTIMindtree |
IDBI Capital
|
5033.80 | 5295.00 | 4533.80 (11.03%) | 5.19 |
Buy
|
||||
| 24 Apr 2025 | Laurus Labs |
Motilal Oswal
|
597.05 | 750.00 | 645.50 (-7.51%) | 25.62 |
Buy
|
FDF/CDMO drives earnings; ends FY25 on strong note
Motilal Oswal
Laurus Lab (LAURUS) delivered a second consecutive quarter with betterthan-expected performance, led by healthy traction in the Formulation (FDF)/API segment. Despite softer-than-expected performance in the CDMO business during 4QFY25, the quarterly sales run rate continued its uptrend.
|
|||
|
more
loading
|
|||||||||||
* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.